Rezolute expands leadership team with appointment of daron evans, ms, mba, as chief financial officer

Redwood city, calif., jan. 24, 2024 (globe newswire) -- rezolute, inc. (nasdaq: rzlt), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of daron evans, ms, mba, to its leadership team as chief financial officer as well as the grant of share options as a material inducement for his appointment (the “inducement grant”).
RZLT Ratings Summary
RZLT Quant Ranking